Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
Aim: To observe the efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment for patients with human epidermal growth factor receptor 2 (HER-2) negative advanced gastric cancer.Methods: 80 eligible patients with HER-2 negative advanced gastric cancer admitted to Jing...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2023.1611114/full |
| _version_ | 1797218159211577344 |
|---|---|
| author | Guohu Han Guohu Han Changchun Sun Lihua Cui Yufeng Huang Lijiang Yu Shenzha Liu Min Tao Min Tao |
| author_facet | Guohu Han Guohu Han Changchun Sun Lihua Cui Yufeng Huang Lijiang Yu Shenzha Liu Min Tao Min Tao |
| author_sort | Guohu Han |
| collection | DOAJ |
| description | Aim: To observe the efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment for patients with human epidermal growth factor receptor 2 (HER-2) negative advanced gastric cancer.Methods: 80 eligible patients with HER-2 negative advanced gastric cancer admitted to Jingjiang People’s Hospital Affiliated with Yangzhou University-from March 2021 to March 2022 were selected, and they were divided into the control group (n = 40, apatinib) and experimental group (n = 40, apatinib plus deep hyperthermia) on the basis of random number table method. The levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and vascular endothelial growth factor (VEGF) were monitored, and the efficacy of the two groups was analyzed by referring to Karnofsky performance status (KPS), overall survival (OS) and disease control rate (DCR) before and after treatment.Results: The levels of CEA, CA199, and VEGF in both groups were lower after treatment than before (p < 0.05), and lower (CEA: 8.85 ± 1.36 vs. 12.87 ± 1.23, CA199: 34.19 ± 4.68 vs. 50.11 ± 5.73, VEGF: 124.8 ± 18.03 vs. 205.9 ± 19.91) in the experimental group than in the control group (p < 0.05). The DCR and KPS of the patients in the experimental group were significantly higher (DCR: 62.50% vs. 40.00%; KPS: 83.25 ± 1.15 vs. 76.25 ± 1.17) than in the control group (p < 0.05). In survival analysis, patients with control group had shorter OS than the experimental group. (median 5.65 vs. 6.50 months; hazard ratio [HR], 1.63 [95% confidence interval (CI) 1.02–2.60], p = 0.0396).Conclusion: The application of low-dose apatinib plus deep hyperthermia for patients with HER-2 negative gastric cancer who failed second-line treatment should be a promising option. |
| first_indexed | 2024-04-24T12:13:19Z |
| format | Article |
| id | doaj.art-30522adab63245e487e4dbc83cf114b9 |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T12:13:19Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-30522adab63245e487e4dbc83cf114b92024-04-08T09:40:38ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072023-07-012910.3389/pore.2023.16111141611114Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancerGuohu Han0Guohu Han1Changchun Sun2Lihua Cui3Yufeng Huang4Lijiang Yu5Shenzha Liu6Min Tao7Min Tao8Department of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, Jiangsu, ChinaDepartment of Oncology, Jingjiang People’s Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, ChinaDepartment of Oncology, Jingjiang People’s Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, ChinaDepartment of Oncology, Jingjiang People’s Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, ChinaDepartment of Oncology, Jingjiang People’s Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, ChinaDepartment of Oncology, Jingjiang People’s Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, ChinaDepartment of Oncology, Jingjiang People’s Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, ChinaDepartment of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, Jiangsu, ChinaDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaAim: To observe the efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment for patients with human epidermal growth factor receptor 2 (HER-2) negative advanced gastric cancer.Methods: 80 eligible patients with HER-2 negative advanced gastric cancer admitted to Jingjiang People’s Hospital Affiliated with Yangzhou University-from March 2021 to March 2022 were selected, and they were divided into the control group (n = 40, apatinib) and experimental group (n = 40, apatinib plus deep hyperthermia) on the basis of random number table method. The levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and vascular endothelial growth factor (VEGF) were monitored, and the efficacy of the two groups was analyzed by referring to Karnofsky performance status (KPS), overall survival (OS) and disease control rate (DCR) before and after treatment.Results: The levels of CEA, CA199, and VEGF in both groups were lower after treatment than before (p < 0.05), and lower (CEA: 8.85 ± 1.36 vs. 12.87 ± 1.23, CA199: 34.19 ± 4.68 vs. 50.11 ± 5.73, VEGF: 124.8 ± 18.03 vs. 205.9 ± 19.91) in the experimental group than in the control group (p < 0.05). The DCR and KPS of the patients in the experimental group were significantly higher (DCR: 62.50% vs. 40.00%; KPS: 83.25 ± 1.15 vs. 76.25 ± 1.17) than in the control group (p < 0.05). In survival analysis, patients with control group had shorter OS than the experimental group. (median 5.65 vs. 6.50 months; hazard ratio [HR], 1.63 [95% confidence interval (CI) 1.02–2.60], p = 0.0396).Conclusion: The application of low-dose apatinib plus deep hyperthermia for patients with HER-2 negative gastric cancer who failed second-line treatment should be a promising option.https://www.por-journal.com/articles/10.3389/pore.2023.1611114/fullapatinibdeep hyperthermiagastric cancerefficacy evaluationprognosis |
| spellingShingle | Guohu Han Guohu Han Changchun Sun Lihua Cui Yufeng Huang Lijiang Yu Shenzha Liu Min Tao Min Tao Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer Pathology and Oncology Research apatinib deep hyperthermia gastric cancer efficacy evaluation prognosis |
| title | Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer |
| title_full | Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer |
| title_fullStr | Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer |
| title_full_unstemmed | Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer |
| title_short | Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer |
| title_sort | efficacy of the low dose apatinib plus deep hyperthermia as third line or later treatment in her 2 negative advanced gastric cancer |
| topic | apatinib deep hyperthermia gastric cancer efficacy evaluation prognosis |
| url | https://www.por-journal.com/articles/10.3389/pore.2023.1611114/full |
| work_keys_str_mv | AT guohuhan efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT guohuhan efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT changchunsun efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT lihuacui efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT yufenghuang efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT lijiangyu efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT shenzhaliu efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT mintao efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer AT mintao efficacyofthelowdoseapatinibplusdeephyperthermiaasthirdlineorlatertreatmentinher2negativeadvancedgastriccancer |